TY - JOUR
T1 - Cost Effectiveness of Transplant, Conventional Chemotherapy, and Novel Agents in Multiple Myeloma
T2 - A Systematic Review
AU - Fu, Shuangshuang
AU - Wu, Chi Fang
AU - Wang, Michael
AU - Lairson, David R.
N1 - Funding Information:
The authors acknowledge the assistance with the literature search provided by Greg Pratt in the Research Medical Library, and the editorial services provided by Sarah Bronson in Scientific Publications at The University of Texas MD Anderson Cancer Center.
Publisher Copyright:
© 2019, Springer Nature Switzerland AG.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Background: Treatments for multiple myeloma (MM) have been rapidly evolving. Newly developed treatment regimens are likely to be more effective but also cost more than conventional therapies. Objective: We conducted a systematic review to compare the cost effectiveness of different classes of MM treatment. Methods: We searched the PubMed, MEDLINE, Web of Science, and EMBASE databases for studies published during 1990–2018 comparing the cost effectiveness of transplant, chemotherapeutic and novel MM treatments. Titles and abstracts were independently reviewed for eligibility by two investigators. The quality of the included studies was evaluated using the 16-item, validated Quality of Health Economics Studies instrument. Results: Twenty-four publications were included in the systematic review and summarized according to treatment regimen and line. For first-line treatment, transplant was the most cost-effective option for transplant-eligible MM patients [the incremental cost-effectiveness ratio (ICER) was $4053–€45,460 per quality-adjusted life-year (QALY) gained, and $3848–$72,852 per life-year gained (LYG)], and the ICER for novel agents compared with conventional chemotherapy was $59,076 per QALY and $220,681 per LYG. For second-line treatment, in comparisons of novel agent-based regimens, ICERs were inconsistent. However, bortezomib-based regimens, lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone were each cost effective compared with dexamethasone alone (ICERs showed cost saving, £30,153 per QALY gained, and €39,911 per LYG, respectively). Conclusions: For transplant-eligible MM patients, transplant is a cost-effective first-line treatment. More cost-effectiveness analyses comparing novel agents in the first-line treatment regimen are warranted to determine which agent or regimen is the most cost effective. In the second-line setting, it is unclear which novel agent-based regimen is most cost effective, but bortezomib-based regimens, lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone were each cost effective compared with dexamethasone alone.
AB - Background: Treatments for multiple myeloma (MM) have been rapidly evolving. Newly developed treatment regimens are likely to be more effective but also cost more than conventional therapies. Objective: We conducted a systematic review to compare the cost effectiveness of different classes of MM treatment. Methods: We searched the PubMed, MEDLINE, Web of Science, and EMBASE databases for studies published during 1990–2018 comparing the cost effectiveness of transplant, chemotherapeutic and novel MM treatments. Titles and abstracts were independently reviewed for eligibility by two investigators. The quality of the included studies was evaluated using the 16-item, validated Quality of Health Economics Studies instrument. Results: Twenty-four publications were included in the systematic review and summarized according to treatment regimen and line. For first-line treatment, transplant was the most cost-effective option for transplant-eligible MM patients [the incremental cost-effectiveness ratio (ICER) was $4053–€45,460 per quality-adjusted life-year (QALY) gained, and $3848–$72,852 per life-year gained (LYG)], and the ICER for novel agents compared with conventional chemotherapy was $59,076 per QALY and $220,681 per LYG. For second-line treatment, in comparisons of novel agent-based regimens, ICERs were inconsistent. However, bortezomib-based regimens, lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone were each cost effective compared with dexamethasone alone (ICERs showed cost saving, £30,153 per QALY gained, and €39,911 per LYG, respectively). Conclusions: For transplant-eligible MM patients, transplant is a cost-effective first-line treatment. More cost-effectiveness analyses comparing novel agents in the first-line treatment regimen are warranted to determine which agent or regimen is the most cost effective. In the second-line setting, it is unclear which novel agent-based regimen is most cost effective, but bortezomib-based regimens, lenalidomide plus dexamethasone, and pomalidomide plus dexamethasone were each cost effective compared with dexamethasone alone.
UR - http://www.scopus.com/inward/record.url?scp=85070489005&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070489005&partnerID=8YFLogxK
U2 - 10.1007/s40273-019-00828-y
DO - 10.1007/s40273-019-00828-y
M3 - Review article
C2 - 31392666
AN - SCOPUS:85070489005
SN - 1170-7690
VL - 37
SP - 1421
EP - 1449
JO - PharmacoEconomics
JF - PharmacoEconomics
IS - 12
ER -